Neuspera Medical

Executive Summary

Neuspera Medical is a private medical device company based in San Jose, California, focused on developing an integrated sacral neuromodulation (iSNM) system for urinary urge incontinence (UUI), a symptom of overactive bladder (OAB). Founded in 2013, the company has pioneered a proprietary wireless powering technology that enables a smart, battery-free implant paired with an external wearable. This innovation eliminates the need for implanted batteries, reducing device size and potentially extending implant longevity. Neuspera’s iSNM system received FDA approval in June 2025, positioning it as a next-generation alternative to traditional sacral neuromodulation devices. The company targets a large addressable market of millions of UUI patients who have failed conservative therapies, and its wireless platform could improve patient comfort and procedural efficiency. With FDA approval secured, Neuspera is now focused on commercial launch and market penetration. The immediate priority is to initiate initial commercial procedures and establish early clinical adoption. Key near-term milestones include securing Medicare reimbursement to expand patient access, and potentially forming strategic partnerships to leverage manufacturing and distribution capabilities. The company’s differentiated technology and validated regulatory pathway suggest strong commercial potential. However, execution risks remain, including competition from established players and the need to demonstrate real-world outcomes to drive adoption. Overall, Neuspera is well-positioned to disrupt the neuromodulation space with its innovative wireless approach.

Upcoming Catalysts (preview)

• Q3 2026First commercial implant of iSNM system90% success
• Q4 2026Medicare reimbursement coverage decision70% success
• Q1 2027Strategic partnership or licensing deal60% success